{"id":"duaconce-daily-gel","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Skin irritation/erythema"},{"rate":"5-10","effect":"Dryness"},{"rate":"3-8","effect":"Peeling"},{"rate":"2-5","effect":"Burning/stinging"}]},"_chembl":{"chemblId":"CHEMBL1189432","moleculeType":"Small molecule","molecularWeight":"337.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively killing Propionibacterium acnes. Benzoyl peroxide generates reactive oxygen species that have broad antimicrobial activity and also help reduce sebum production and comedone formation. The combination provides synergistic antibacterial and anti-inflammatory effects.","oneSentence":"Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease inflammation in acne lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:10.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT02578043","phase":"PHASE1","title":"A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-04","conditions":"Acne Vulgaris","enrollment":844},{"nctId":"NCT01015638","phase":"PHASE4","title":"Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":36},{"nctId":"NCT01915732","phase":"PHASE3","title":"A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Acne Vulgaris","enrollment":1018},{"nctId":"NCT00964223","phase":"PHASE4","title":"A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Duac™Once Daily Gel","genericName":"Duac™Once Daily Gel","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease inflammation in acne lesions. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}